BOONTON, N.J., May 21, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced the Company's Vice President of Research and Development, Nozer Mehta, Ph.D., will be presenting at the TIDES 2012 conference for the oligonucleotide and peptide industry, being held at the Mandalay Bay Resort and Casino in Las Vegas, NV.
TIDES 2012 is the premier conference focused on oligonucleotide and peptide-based therapeutics, serving as an annual gathering point for the leading companies, academics and researchers in the field. As a key industry opinion and thought leader, Dr. Mehta will address the conference attendees on topics of critical importance to the applications and alternate delivery routes of peptide therapeutics.
Target Peptide Optimization and Recombinant Manufacturing of an Orally Delivered Peptide for the Treatment of Obesity
Spotlight Presentation – Emerging Technologies Showcase – Peptides
Alternative Delivery Platforms for Oligonucleotide and Peptide Therapeutics
Strategy Discussion Forum
"TIDES 2012 is an ideal forum for showcasing advancements in peptide therapeutics, including Unigene's oral peptide delivery technology which we have branded as Peptelligence™," said Dr. Mehta. "Without question, the oral delivery of peptide therapeutics is the most significant recent advancement in the peptide space as it offers the opportunity to redefine the treatment regimen and increase the market potential for numerous debilitating, chronic conditions. Unigene is at the forefront of this paradigm shift, making TIDES 2012 an extremely valuable scientific and business development event for building awareness among companies and institutions that are developing next-generation peptide compounds and looking for new ways to expand existing peptide franchises."
About Unigene Laboratories, Inc.:
Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform. Peptelligence™ encompasses extensive intellectual property covering drug delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence™ assets include proprietary oral and nasal peptide drug delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.
Unigene Laboratories, Inc.
VP, Investor Relations and Business Administration
|SOURCE Unigene Laboratories, Inc.|
Copyright©2010 PR Newswire.
All rights reserved